<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947995</url>
  </required_header>
  <id_info>
    <org_study_id>D-P200110-MCCGW-HP-GC</org_study_id>
    <nct_id>NCT04947995</nct_id>
  </id_info>
  <brief_title>Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric Cancer</brief_title>
  <acronym>MONITOR- GAC</acronym>
  <official_title>Validation of a Plasma-based Multiomics Assay and Risk Scoring Model for Screening of Gastric Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneCast Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneCast Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, case-control study intended to develop and validate a blood-based&#xD;
      multi-omics assay and computational model for early detection of gastric cancer.&#xD;
      Approximately 450 subjects who receive esophageogastroscopy (EGD) will be enrolled and&#xD;
      assigned to three arms including gastric cancer, precancerous lesion, and healthy control&#xD;
      based on the diagnosis of EGD and histological results. Cell free DNA will be extracted from&#xD;
      peripheral blood of all participants and assayed by next-generation sequencing for biomarkers&#xD;
      including somatic mutation, methylation, and chromosome instability signals. In the first&#xD;
      stage a multi-omics models will be developed for classification between malignancy group and&#xD;
      control groups, and between precancerous group and healthy control. Sensitivity and&#xD;
      specificity of the model will be evaluated in an independent validation group in the second&#xD;
      stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The sensitivity and specificity of blood-based multi-omics assay for early detection of gastric cancer with comparison to EGD and/or histological diagnosis.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Gastric cancer group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Precancerous lesion group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ctDNA multi-omics test</intervention_name>
    <description>The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.</description>
    <arm_group_label>Gastric cancer group</arm_group_label>
    <arm_group_label>Healthy group</arm_group_label>
    <arm_group_label>Precancerous lesion group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged≥40 who will receive EGD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age≥40&#xD;
&#xD;
          -  Received EGD;&#xD;
&#xD;
          -  Subjects must have given written informed consent, and the subjects compliance are&#xD;
             good.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who could not accept EGD;&#xD;
&#xD;
          -  Subjects who had previously undergone total or partial gastrectomy;&#xD;
&#xD;
          -  There are other serious acute or chronic medical or mental diseases or laboratory&#xD;
             abnormalities that may interfere with the interpretation of the research results and&#xD;
             make the subjects unsuitable for the study in the judgment of the researchers;&#xD;
&#xD;
          -  Subjects with a history of malignant tumor or two or more malignant tumors at the same&#xD;
             time;&#xD;
&#xD;
          -  Pregnant subjects;&#xD;
&#xD;
          -  Subjects who had a history of bone marrow or organ transplantation, or had a history&#xD;
             of blood transfusion one month before enrollment.&#xD;
&#xD;
          -  The subjects with incomplete clinical data collection or other reasons judged by the&#xD;
             researchers are not suitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Shen</last_name>
    <phone>400-080-0660</phone>
    <email>shen.ning1@genecast.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Yao</last_name>
      <phone>13511073309</phone>
      <email>yaofang99@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

